Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $298.09 Average PT from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus recommendation of “Moderate Buy” from the twenty-five research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $298.61.

A number of equities research analysts have commented on ALNY shares. Bank of America raised their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Cantor Fitzgerald restated a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Raymond James raised their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Finally, Barclays upped their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $237.98 on Friday. The firm has a 50 day moving average of $248.88 and a 200-day moving average of $259.65. The company has a market cap of $30.69 billion, a price-to-earnings ratio of -90.83 and a beta of 0.34. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The company’s quarterly revenue was down 33.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.15 earnings per share. On average, equities analysts forecast that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock valued at $2,540,455 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Souders Financial Advisors grew its stake in Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 36 shares in the last quarter. Huntington National Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the last quarter. SYM FINANCIAL Corp grew its position in Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 55 shares in the last quarter. Lindbrook Capital LLC increased its stake in Alnylam Pharmaceuticals by 11.1% in the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 57 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock worth $1,532,000 after purchasing an additional 58 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.